Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director · See Remarks | December 21, 2023 | December 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date December 21, 2023 · Filed December 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,378 |
Reported balance
After 2023-12-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-21 · Purchase · Acquired 1,886 · Balance 33,378 F1: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19 · Expires 2030-12-21 | Direct | 1,886 |
Reported balance
After 2023-12-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-21 · Purchase · Acquired 1,886 · Balance 1,886 F2: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.
F2: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2023 Filed Dec 26, 2023 21:05 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | PurchaseWarrants (right to buy) · Derivative | 1,886 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001104659-23-129186 · tm2333679-1_4seq1.xml · derivative · entry 2 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,886 Underlying: Common Stock · 1,886 shares Expires 2030-12-21 F2 · price: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:05 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | PurchaseCommon Stock | 1,886 | $3.32 | $6,252.09 |
DisclosureSEC source: 0001104659-23-129186 · tm2333679-1_4seq1.xml · nonDerivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,378 F1 · security: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:57 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 70,200 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077657 · tm2320411-6_4seq1.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2033-06-30 F1 · price: The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:19 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 31,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009914 · tm235262-3_4seq1.xml · nonDerivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,492 F1 · shares: The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement. F2 · balance_after: Includes 292 shares of common stock and 31,200 restricted stock units. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 21:19 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-21-150001 · tm2135363d2_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-13 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:25 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001104659-20-135750 · tm2038414d2_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-12-11 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:00 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantOption · Derivative | 11,980 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-19-071119 · tm1924755d1_4.xml · derivative · entry 2 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,980 Underlying: Common Stock · 11,980 shares Expires 2028-02-22 F2 · price: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares. F2 · derivative.exercise_date: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares. Read SEC document |
| December 05, 2019 Filed Dec 10, 2019 02:00 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantOption · Derivative | 13,022 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-19-071119 · tm1924755d1_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,022 Underlying: Common Stock · 13,022 shares Expires 2027-12-29 F1 · price: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares. F1 · derivative.exercise_date: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 14:28 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantOption · Derivative | 270,079 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001144204-19-000790 · tv510491_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,079 Underlying: Common Stock · 270,079 shares Expires 2029-01-04 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:28 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantOption · Derivative | 11,980 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001144204-19-000790 · tv510491_4.xml · derivative · entry 3 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,980 Underlying: Common Stock · 11,980 shares Expires 2028-02-22 F4 · price: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,980 shares. F4 · derivative.exercise_date: On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,980 shares. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 14:28 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantOption · Derivative | 13,021 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-19-000790 · tv510491_4.xml · derivative · entry 2 McBarron Paul · CIK 0001357397 · Director · E. VP, Fin, CFO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021 Underlying: Common Stock · 13,021 shares Expires 2027-12-29 F3 · price: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 13,021 shares. F3 · derivative.exercise_date: On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 13,021 shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.